Table 1.
Clinical characteristics of discovery cohort.
| Total | DCB | NDB | P-value | |
|---|---|---|---|---|
| Histology | ||||
| Squamous | 87 (82.1%) | 44 (86.3%) | 43 (78.2%) | 0.32 |
| Non-squamous | 19 (17.9%) | 7 (13.7%) | 12 (21.8%) | |
| Sex | ||||
| Female | 54 (50.9%) | 26 (51.0%) | 28 (50.9%) | 1 |
| Male | 52 (49.1%) | 25 (49.0%) | 27 (49.1%) | |
| Smoking Status | ||||
| Current/Former | 85 (80.2%) | 43 (84.3%) | 42 (76.4%) | 0.34 |
| Never | 21 (19.8%) | 8 (15.7%) | 13 (23.6%) | |
| PD L1 expression | ||||
| Strong | 18 (17.0%) | 14 (27.5%) | 4 (7.3%) | 0.045 |
| Weak | 48 (45.3%) | 21 (41.2%) | 27 (49.1%) | |
| Negative | 31 (29.2%) | 12 (23.5%) | 19 (34.5%) | |
| Unknown | 9 (8.5%) | 4 (7.84%) | 5 (9.1%) | |
| Best Overall Response | ||||
| CR/PR | 34 (32.1%) | 34 (66.7%) | 0 (0.0%) | <0.001 |
| PD/NE | 36 (34.0%) | 0 (0.0%) | 36 (65.5%) | |
| SD | 36 (34.0%) | 17 (33.3%) | 19 (34.5%) | |
| Treatment | ||||
| PD-1 blockade | 31 (29.2%) | 14 (27.5s%) | 17 (30.9%) | 0.83 |
| PD-1 plus CTLA-4 blockade | 75 (70.8%) | 37 (72.5%) | 38 (69.1%) | |
CR, complete response; CTLA-4, cytotoxic T-cell lymphocyte-4; DCB, durable clinical benefit; NDB, no durable benefit; NE, not evaluable; PD, progressive disease; PD-1, programmed cell death-1; PR, partial response; SD, stable disease.